We are live on ! Find out more
WVE icon

Wave Life Sciences

60 hedge funds and large institutions have $220M invested in Wave Life Sciences in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 27 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,767% more call options, than puts

Call options by funds: $146K | Put options by funds: $3K

131% more capital invested

Capital invested by funds: $95.3M → $220M (+$125M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.23% less ownership

Funds ownership: 78.39%78.16% (-0.23%)

27% less funds holding

Funds holding: 8260 (-22)

59% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 27

63% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 32

Holders
60
Holders Change
-22
Holders Change %
-26.83%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
11
Reduced
27
Closed
32
Calls
$146K
Puts
$3K
Net Calls
+$143K
Net Calls Change
+$104K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$55.9M +$18.1M +9,426,802 +121%
MCM
2
M28 Capital Management
Connecticut
$26.9M +$4.68M +2,432,204 +42%
MC
3
Maverick Capital
Texas
$25.4M +$4.25M +2,211,830 +40%
6CM
4
683 Capital Management
New York
$24.4M +$13.6M +7,059,201 +1,528%
BG
5
Bellevue Group
Switzerland
$14.6M -$132K -68,400 -1%
Primecap Management
6
Primecap Management
California
$14.4M -$259K -134,467 -3%
AG
7
Artal Group
Luxembourg
$9.75M +$3.85M +2,000,000 +200%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$8.93M +$4.42M +2,297,141 +510%
KCM
9
Kynam Capital Management
New Jersey
$5.51M -$414K -214,993 -11%
BlackRock
10
BlackRock
New York
$4.34M -$3.08M -1,602,299 -55%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$4.02M +$2.25M +1,171,432 +1,759%
PIM
12
Platinum Investment Management
Australia
$3.69M -$386K -200,757 -15%
Millennium Management
13
Millennium Management
New York
$3.49M +$594K +308,975 +40%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$3.06M -$290K -150,835 -14%
LCM
15
Laurion Capital Management
New York
$2.83M +$1.68M +871,500 New
Vanguard Group
16
Vanguard Group
Pennsylvania
$2.34M -$349K -181,674 -20%
JP Morgan Chase
17
JP Morgan Chase
New York
$1.55M -$774K -402,528 -46%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.45M -$596K -309,688 -41%
NM
19
Newtyn Management
New York
$1.31M +$776K +403,553 New
DCM
20
DAFNA Capital Management
California
$1.21M -$34.2K -17,800 -5%
E
21
Ergoteles
New York
$635K +$376K +195,495 New
WM
22
WS Management
Florida
$626K +$289K +150,000 +351%
Renaissance Technologies
23
Renaissance Technologies
New York
$532K -$80K -41,594 -20%
State Street
24
State Street
Massachusetts
$457K -$1.08M -559,920 -80%
IC
25
Ikarian Capital
Texas
$318K -$1.83M -950,000 -91%

WVE Hedge Fund Activity: Q2 2022 in Review

60 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Wave Life Sciences (WVE) for Q2 2022, worth a combined $220M — up 131% from $95.3M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of WVE and 12 opened new positions — a net loss of 20 holders — while 27 trimmed existing stakes and 11 added.

The largest buyer was RA Capital Management, adding an estimated $18.1M. The largest seller was BlackRock, cutting an estimated $3.08M.

  • 60 institutional investors held Wave Life Sciences (WVE) as of Q2 2022, down from 82 in Q1 2022.
  • Funds reported $220M of Wave Life Sciences stock for Q2 2022, up 131% quarter-over-quarter.
  • 12 funds opened new Wave Life Sciences positions in Q2 2022 and 32 closed out, a net change of -20 holders.
  • The largest Wave Life Sciences buyer in Q2 2022 was RA Capital Management, an estimated $18.1M added.
  • The largest Wave Life Sciences seller in Q2 2022 was BlackRock, an estimated $3.08M sold.

Based on aggregated 13F filings for Q2 2022.